ImmunityBio, Inc. IBRX U.S. — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s u.s. — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s U.S. — revenue?
- ImmunityBio, Inc. (IBRX) reported U.S. — revenue of $44.18M in Q1 2026.
- How has ImmunityBio, Inc.'s U.S. — revenue changed year-over-year?
- ImmunityBio, Inc.'s U.S. — revenue increased by 167.5% year-over-year, from $16.52M to $44.18M.
- What is the long-term trend for ImmunityBio, Inc.'s U.S. — revenue?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s U.S. — revenue has grown at a 317.2% compound annual growth rate (CAGR), from $373K to $113.01M.
- What does U.S. — revenue mean?
- This metric represents the total gross income generated from the sale of products, services, or licensing arrangements within the United States geographic segment. It serves as a primary indicator of market penetration and commercial adoption for the company's therapeutic platforms in its domestic market. Tracking this revenue stream is essential for evaluating the transition from clinical-stage development to commercial-stage operations.